Jianning Yang

1.0k total citations
29 papers, 693 citations indexed

About

Jianning Yang is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jianning Yang has authored 29 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 13 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Jianning Yang's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (6 papers) and Advanced Breast Cancer Therapies (5 papers). Jianning Yang is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (6 papers) and Advanced Breast Cancer Therapies (5 papers). Jianning Yang collaborates with scholars based in United States, Australia and Japan. Jianning Yang's co-authors include Rod Humerickhouse, Sari H. Enschede, Andrew W. Roberts, John F. Seymour, Hao Xiong, Todd Busman, Brad S. Kahl, Walid M. Awni, Sven Mensing and Peter Noertersheuser and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jianning Yang

27 papers receiving 688 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jianning Yang United States	14	320	254	237	220	125	29	693
Cathy E. Nolan United States	6	384 1.2×	113 0.4×	117 0.5×	206 0.9×	68 0.5×	8	585
Zhihong Zeng United States	6	467 1.5×	119 0.5×	114 0.5×	111 0.5×	65 0.5×	13	652
Lourdes Mendez United States	10	309 1.0×	112 0.4×	191 0.8×	218 1.0×	190 1.5×	34	609
Swaroop Vakkalanka United States	11	210 0.7×	266 1.0×	244 1.0×	132 0.6×	131 1.0×	46	551
Cory Mavis United States	16	441 1.4×	159 0.6×	245 1.0×	285 1.3×	120 1.0×	74	754
Silvia L. Locatelli Italy	15	373 1.2×	67 0.3×	134 0.6×	146 0.7×	144 1.2×	42	616
Scott Ackler United States	8	472 1.5×	76 0.3×	94 0.4×	233 1.1×	75 0.6×	10	625
Pablo G. Longo Italy	11	390 1.2×	739 2.9×	363 1.5×	133 0.6×	463 3.7×	16	1.0k
Andrew Capen United States	9	511 1.6×	121 0.5×	103 0.4×	212 1.0×	42 0.3×	19	724
René Galien Belgium	8	123 0.4×	174 0.7×	83 0.4×	308 1.4×	159 1.3×	32	706

Countries citing papers authored by Jianning Yang

Since Specialization

Citations

This map shows the geographic impact of Jianning Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianning Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianning Yang more than expected).

Fields of papers citing papers by Jianning Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianning Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianning Yang. The network helps show where Jianning Yang may publish in the future.

Co-authorship network of co-authors of Jianning Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jianning Yang. A scholar is included among the top collaborators of Jianning Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianning Yang. Jianning Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Mingyu, Jianning Yang, Sui Li, et al.. (2025). Isocucurbitacin B inhibits gliomas through the promotion of anoikis by targeting caveolin 1. Cancer Letters. 629. 217873–217873. 5 indexed citations

Takeuchi, Masato, et al.. (2025). Population PK and Exposure‐Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/ GEJ Adenocarcinoma. Clinical and Translational Science. 18(7). e70280–e70280. 1 indexed citations

Grimaldi, Christine, Susan Richards, Daniel Baltrukonis, et al.. (2025). IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment. Clinical Pharmacology & Therapeutics. 117(6). 1596–1604.

Richards, Susan, Lora Hamuro, Karey Kowalski, et al.. (2025). IQ Survey Results on Current Industry Practices: Part 2—Quantitative Evaluations of Immunogenicity Assessment. Clinical Pharmacology & Therapeutics. 117(6). 1605–1613. 1 indexed citations

Galluppi, Gerald R., Malidi Ahamadi, Nageshwar Budha, et al.. (2024). Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program. Clinical Pharmacology & Therapeutics. 116(2). 282–288. 6 indexed citations

Marron, Thomas U., et al.. (2024). Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4.. Journal of Clinical Oncology. 42(16_suppl). TPS2670–TPS2670. 1 indexed citations

Yang, Jianning, Akihiro Yamada, Samuel J. Klempner, et al.. (2024). Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab.. Journal of Clinical Oncology. 42(3_suppl). 316–316. 3 indexed citations

Lee, Keun‐Wook, Samuel J. Klempner, Jianning Yang, et al.. (2021). Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).. Journal of Clinical Oncology. 39(15_suppl). e16078–e16078. 2 indexed citations

Tolcher, Anthony W., Patricia LoRusso, Jennifer A. Arzt, et al.. (2015). Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study. Cancer Chemotherapy and Pharmacology. 76(5). 1041–1049. 26 indexed citations

10.

Roberts, Andrew W., Ranjana H. Advani, Brad S. Kahl, et al.. (2015). Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20⁺ lymphoid malignancies. British Journal of Haematology. 170(5). 669–678. 79 indexed citations

11.

Yang, Jianning, Peter Noertersheuser, Sven Mensing, et al.. (2014). Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemotherapy and Pharmacology. 74(3). 593–602. 118 indexed citations

12.

Cleary, James M., Caio Max S. Rocha Lima, Herbert I. Hurwitz, et al.. (2014). A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Investigational New Drugs. 32(5). 937–945. 59 indexed citations

13.

Vlahovic, Gordana, Vassiliki Karantza, Ding Wang, et al.. (2014). A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Investigational New Drugs. 32(5). 976–984. 46 indexed citations

14.

Ma, Shuo, John F. Seymour, Mark C. Lanasa, et al.. (2014). ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.. Journal of Clinical Oncology. 32(15_suppl). 7013–7013. 13 indexed citations

15.

Vos, Sven de, Christopher R. Flowers, Ding Wang, et al.. (2014). The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma. Blood. 124(21). 1722–1722. 12 indexed citations

16.

Salem, Ahmed Hamed, Jianning Yang, Alison M. Graham, et al.. (2014). Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.. PubMed. 34(4). 2001–6. 3 indexed citations

17.

Seymour, John F., Matthew S. Davids, John M. Pagel, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7018–7018. 20 indexed citations

18.

Davids, Matthew S., John F. Seymour, John F. Gerecitano, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 31(15_suppl). 8520–8520. 10 indexed citations

19.

Davids, Matthew S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood. 120(21). 304–304. 28 indexed citations

20.

Yang, Jianning, Hao Xiong, Andrew Krivoshik, et al.. (2011). Abstract 1300: Evaluating the relative bioavailability of a new formulation of navitoclax (ABT-263) in both cancer patients and healthy volunteers. Cancer Research. 71(8_Supplement). 1300–1300. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact